Observational studyRadiation oncology (London, England)2020
1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.
Observational study in Radiation oncology (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 2 syntheses or guidelines pooled it, 140 citations in OpenAlex.
- Clinical application of MR-Linac in tumor radiotherapy: a systematic review.Radiation oncology (London, England) · 2023Pooled it
- Economic Evaluations of Magnetic Resonance Image-Guided Radiotherapy (MRIgRT): A Systematic Review.International journal of environmental research and public health · 2022Pooled it
- Magnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for prostate, pElvis & metastases (MRgSMART-PEM) in prostate cancer: a prospective phase II study.Radiation oncology (London, England) · 2026Trial
- Phase II prospective trial "Give Me Five" short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218).Medical oncology (Northwood, London, England) · 2020Trial
- Daily adaptive 1.5 T MR-Linac image-guided re-irradiation for prostate cancer: an international retrospective experience.Clinical and translational radiation oncology · 2027Article
- Initial Experience with MR-Guided or CT-Guided Stereotactic Body Radiotherapy for Prostate Cancer.Current oncology (Toronto, Ont.) · 2026Article
- CBCT based online daily adaptive treatment improves target coverage with limited benefit for OAR protection in SBRT prostate cancer.Radiation oncology (London, England) · 2026Article
- Impact of field number and monitor units per segment on magnetic resonance-guided hypofractionated stereotactic radiotherapy for brain metastases: plan quality, deliverability, and robustness trade-offs.Quantitative imaging in medicine and surgery · 2026Article
- Impact of Adaptive Radiation Therapy on Toxicity in Prostate Cancer: A Scoping Review.Biomedicines · 2026Review
- Salvage stereotactic MR-Guided adaptive radiotherapy (SMART) re-irradiation for locally recurrent prostate Cancer: Clinical and dosimetric outcomes.Clinical and translational radiation oncology · 2026Review
- Impact evaluation of intra-fractional variation on online adaptive radiotherapy for postoperative cervical and endometrial cancer.World journal of clinical oncology · 2025Article
- CBCT-Based Online Adaptive, Ultra-Hypofractionated Radiotherapy for Prostate Cancer: First Clinical Experiences.Medicina (Kaunas, Lithuania) · 2025Article
- Evaluating dosimetric outcomes: a comparison of CyberKnife, VMAT FFF, and Helical Tomotherapy Radixact for treating localized prostate cancer.La Radiologia medica · 2025Article
- A cone-beam computed tomography based workflow for online adaptive ultra-hypofractionated radiotherapy of prostate cancer.Physics and imaging in radiation oncology · 2025Article
- Article
- Optimizing Workflow for Cone Beam Computed Tomography-Based Online Adaptive Radiation Therapy Toward Reduced Physician Involvement.Advances in radiation oncology · 2025Article
- First clinical application of Comprehensive Motion Management with 1.5T MR-linac on prostate cancer patients treated with radiotherapy: technical aspects and suggested workflow recommendations.La Radiologia medica · 2025Article
- Article
- Auto-Segmentation and Auto-Planning in Automated Radiotherapy for Prostate Cancer.Bioengineering (Basel, Switzerland) · 2025Article
- First-in-Men Online Adaptive Robotic Stereotactic Body Radiation Therapy: Toward Ultrahypofractionation for High-Risk Prostate Cancer Patients.Advances in radiation oncology · 2025Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnity Elekta is a unique magnetic resonance (MR)-linac that conjugates a 1.5 Tesla MR unit with a 7 MV flattening filter free accelerator.A prospective observational study for the clinical use of Elekta Unity is currently ongoing in our department. Herein, we present our preliminary report on the feasibility, quality of life, and patient-reported outcomes measures (PROMs) for localized prostate cancer (PC) treated with stereotactic body radiotherapy (SBRT).
methodsThe SBRT protocol consisted of a 35 Gy schedule delivered in 5 fractions within 2 weeks. Toxicity and quality of life (QoL) were assessed at baseline and after treatment using the Common Terminology Criteria for Adverse Events v5.0, International Prostatic Symptoms Score (IPSS), ICIQ-SF, IIEF-5, and EORTC-QLQ-C30 and PR-25 questionnaires.
resultsBetween October 2019 and January 2020, 25 patients with localized PC were recruited. The median age was 68 years (range, 54-82); 4 were low risk, 11 favorable intermediate risk (IR) and 10 unfavorable IR. Median iPSA was 6.8 ng/ml (range, 1-19), and 9 of these patients (36%) received concurrent androgen deprivation therapy. Median prostate volume was 36 cc (range, 20-61); median baseline IPSS was 5 (range, 0-10). Median time for fraction was 53 min (range, 34-86); adaptive strategy with daily critical structure and target re-contouring and daily replanning (adapt to shape) was performed in all cases. No grade ≥ 3 adverse event was observed, three patients (12%) reported grade 2 acute genitourinary toxicity (urinary frequency, urinary tract pain and urinary retention), while only one patient reported mild rectal pain. No relevant deteriorations were reported in PROMs.
conclusionTo the best of our knowledge, this is the first experience reporting feasibility, clinician-reported outcome measurements, and PROMs for 1.5 T MR-guided adaptive SBRT for localized prostate cancer. The preliminary data collected here report optimal safety and excellent tolerability, as also confirmed by PROMs questionnaires. Moreover, the data on technical feasibility and timing of online daily adapted planning and delivery are promising. More mature data are warranted.
trial registrationDate of approval April 2019 and numbered MRI/LINAC n°23,748.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.